Evaluating Health Outcomes in the Presence of Competing Risks A Review of Statistical Methods and Clinical Applications

被引:172
作者
Varadhan, Ravi [1 ,3 ]
Weiss, Carlos O. [1 ]
Segal, Jodi B. [1 ,2 ]
Wu, Albert W. [1 ,2 ]
Scharfstein, Daniel [3 ]
Boyd, Cynthia [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
关键词
cause-specific hazards; event-free survival; cumulative incidence function; semicompeting risks; comparative effectiveness; CUMULATIVE INCIDENCE FUNCTION; PROPORTIONAL HAZARDS MODEL; FAILURE PROBABILITIES; PROSTATE-CANCER; EVENTS; INFERENCE; TRIALS;
D O I
10.1097/MLR.0b013e3181d99107
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: An evaluation of the effect of a healthcare intervention ( or an exposure) must consider multiple possible outcomes, including the primary outcome of interest and other outcomes such as adverse events or mortality. The determination of the likelihood of benefit from an intervention, in the presence of other competing outcomes, is a competing risks problem. Although statistical methods exist for quantifying the probability of benefit from an intervention while accounting for competing events, these methods have not been widely adopted by clinical researchers. Objectives: ( 1) To demonstrate the importance of considering competing risks in the evaluation of treatment effectiveness, and ( 2) to review appropriate statistical methods, and recommend how they might be applied. Research Design and Methods: We reviewed 3 statistical approaches for analyzing the competing risks problem: (a) cause-specific hazard (CSH), (b) cumulative incidence function ( CIF), and (c) event-free survival (EFS). We compare these methods using a simulation study and a reanalysis of a randomized clinical trial. Results: Simulation studies evaluating the statistical power to detect the effect of intervention under different scenarios showed that: ( 1) CSH approach is best for detecting the effect of an intervention if the intervention only affects either the primary outcome or the competing event; ( 2) EFS approach is best only when the intervention affects both primary and competing events in the same manner; and ( 3) CIF approach is best when the intervention affects both primary and competing events, but in opposite directions. Using data from a randomized controlled trial, we demonstrated that a comprehensive approach using all 3 approaches provided useful insights on the effect of an intervention on the relative and absolute risks of multiple competing outcomes. Conclusions: CSH is the fundamental measure of outcome in competing risks problems. It is appropriate for evaluating treatment effects in the presence of competing events. Results of CSH analysis for primary and competing outcomes should always be reported even when EFS or CIF approaches are called for. EFS is appropriate for evaluating the composite effect of an intervention, only when combining different endpoints is clinically and biologically meaningful, and the treatment has similar effects on all event types. CIF is useful for evaluating the likelihood of benefit from an intervention over a meaningful period. CIF should be used for absolute risk calculations instead of the widely used complement of the Kaplan-Meier (1 - KM) estimator.
引用
收藏
页码:S96 / S105
页数:10
相关论文
共 32 条
[1]   ESTIMATES OF ABSOLUTE CAUSE-SPECIFIC RISK IN COHORT STUDIES [J].
BENICHOU, J ;
GAIL, MH .
BIOMETRICS, 1990, 46 (03) :813-826
[2]  
BYAR DP, 1980, B CANCER, V67, P477
[3]   Prediction of cumulative incidence function under the proportional hazards model [J].
Cheng, SC ;
Fine, JP ;
Wei, LJ .
BIOMETRICS, 1998, 54 (01) :219-228
[4]  
Fine J P, 2001, Biostatistics, V2, P85, DOI 10.1093/biostatistics/2.1.85
[5]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[6]  
FIX EVELYN, 1951, HUMAN BIOL, V23, P205
[7]   Composite outcomes in randomized trials - Greater precision but with greater uncertainty? [J].
Freemantle, N ;
Calvert, M ;
Wood, J ;
Eastaugh, J ;
Griffin, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2554-2559
[8]   Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [J].
Gail, MH ;
Costantino, JP ;
Bryant, J ;
Croyle, R ;
Freedman, L ;
Helzlsouer, K ;
Vogel, V .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) :1829-1846
[9]   ON THE USE OF CAUSE-SPECIFIC FAILURE AND CONDITIONAL FAILURE PROBABILITIES - EXAMPLES FROM CLINICAL ONCOLOGY DATA [J].
GAYNOR, JJ ;
FEUER, EJ ;
TAN, CC ;
WU, DH ;
LITTLE, CR ;
STRAUS, DJ ;
CLARKSON, BD ;
BRENNAN, MF .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1993, 88 (422) :400-409
[10]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO